Healthcare
Amplia Therapeutics Limited(INNMF)
Live Price
Offline$0.08
+0.00% today
1Y Change
-34.43%
Window
Jun 25, 2025 → Jun 23, 2026
- Market Cap
- $80.00M
- Revenue Growth
- -15.0%
- EPS Growth
- +7.8%
- Dividend Yield
- 0.0%
Coverage: 249 bars · Jun 25, 2025 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Amplia Therapeutics Limited (INNMF) is a Healthcare stock with a market cap of $80.00M and listed on OTC. The stock last traded around $0.08 and down 34.4% across the available one-year price window (Jun 25, 2025 → Jun 23, 2026). Baseline metrics include revenue growth of -15.0%, EPS growth of +7.8%, a dividend yield of 0.0%. What stands out right now is revenue -15.0%, EPS +7.8%, free cash flow -34.3% with operating margin -452.9% and ROIC -18.7%. Valuation already assumes a fairly strong business story at price/sales 33.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines INNMF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-15.0% vs +7.6% peer median
Operating Margin
Below sector median
-452.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at -15.0% and EPS is at +7.8%, with operating margin around -452.9%.
Benchmark Edge
INNMF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
INNMF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
INNMF Max Drawdown
-79.58%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for INNMF and SPY.
Company Overview
Amplia Therapeutics Limited
Other OTC
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
- Leadership
- Christopher J. Burns
- IPO Date
- Jan 8, 2021
- Employees
- 1
- Street Address
- 350 Queen Street
- Mailing
- Melbourne, VIC, 3000
- Region
- Melbourne, VIC, AU
- Reporting Currency
- USD
- Investor Line
- 61 3 9123 1140
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 33.5
- Price/Book
- 1.5
Growth
- Revenue
- -15.0%
- EPS
- +7.8%
- Free Cash Flow
- -34.3%
Profitability
- Gross Margin
- 92.6%
- Operating Margin
- -452.9%
- Net Margin
- -333.8%
- ROE
- -24.8%
- ROIC
- -18.7%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 28.17
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.